Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Trial of BioMed rTSST-1 Variant Vaccine in Healthy Adults
NCT02340338Phase 1Completed
- Sponsor
- Biomedizinische Forschung
- Start
- Jul 2014
- Primary completion
- Jun 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rTSST-1 variant vaccine in toxic shock syndrome (TSS) (7 arms), sponsored by Biomedizinische Forschung. Primary endpoint: Number of Participants With Adverse Events as a Measure of Safety and Tolerability. Started Jul 2014; status: completed.
02
Drugs
rTSST-1 variant vaccine
03
Conditions
toxic shock syndrome (TSS)
Beyond the preview
Go deeper on NCT02340338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02340338.